Labcorp expanded its molecular residual disease (MRD) portfolio with nationwide launches of Plasma Detect ID and Plasma Detect Genome assays, designed to detect circulating tumor DNA down to 0.005% allele frequency for post‑treatment surveillance. Saga Diagnostics launched its Pathlight MRD test for colorectal cancer, supported by real‑world CITCCA data, and Watchmaker Genomics released four enzymes optimized for recombinase polymerase amplification (RPA) aimed at point‑of‑care isothermal assays. These product rollouts reflect continued commercial investment in liquid biopsy surveillance and decentralized diagnostics workflows. For readers: tumor‑informed MRD tests use individualized genomic signatures derived from tumor tissue to sensitively track microscopic residual disease in blood and guide adjuvant and surveillance decisions.